

**Table 3** Difference between FD with and without OAB

FD (n = 438)	FD without OAB (n = 348)	FD with OAB (n = 90)	Univariate analysis, Odds Ratio (95% CI)	Multivariate analysis <sup>†</sup> Odds Ratio (95% CI)
IBS-C, n (%)	12 (3.4%)	9 (10.0%)	<b>3.11 (1.27–7.63)</b>	<b>3.08 (1.24–7.63)</b>
IBS-D, n (%)	55 (15.8%)	17 (18.9%)	1.24 (0.68–2.26)	
IBS-M, n (%)	21 (6.0%)	3 (3.3%)	0.54 (0.16–1.84)	
Age, years (mean ± SD)	42.4 ± 8.4	45.1 ± 8.2	<b>1.04 (1.01–1.07)</b>	<b>1.04 (1.01–1.07)</b>
Gender, men, n (%)	147 (42.2%)	41 (45.6%)	1.14 (0.72–1.82)	
Smoking habit, n (%)				
None	257 (73.9%)	71 (78.9%)	ref.	
Light	36 (10.3%)	9 (10.0%)	0.29 (0.42–1.97)	
Heavy	55 (15.8%)	10 (11.1%)	0.66 (0.32–1.37)	
Alcohol habit, n (%)				
None	106 (30.5%)	27 (30.0%)	ref.	
Light	132 (37.9%)	26 (28.9%)	0.91 (0.42–1.40)	
Heavy	110 (31.6%)	37 (41.1%)	1.31 (0.75–2.30)	
BMI, kg m <sup>-2</sup> (mean ± SD)	22.3 ± 3.7	22.1 ± 3.7	0.99 (0.93–1.06)	

<sup>†</sup>Analyzed by multivariable logistic regression model with adjustment for IBS-C and age. Bold values indicate significant associations. FD, functional dyspepsia; OAB, overactive bladder; IBS, irritable bowel syndrome; CI, confidence interval; BMI, body mass index.

and BMI were not associated with overlap of these two conditions.

**Influences of dyspeptic symptoms on the severity of OAB symptoms**

Among participants with OAB, the severity of OAB symptoms in participants with and without dyspeptic symptoms (postprandial fullness, early satiation, epigastric pain, and epigastric burning) is shown in Table 4. The average score of total OABSS in OAB participants with postprandial fullness was significantly higher than that in OAB participants without postprandial fullness. The presence of early satiation, epigastric pain, and epigastric burning also enhanced the scores of total OABSS, although these differences were not significant.

**Table 4** Associations between the severities of OAB and dyspeptic symptoms

OAB (n = 497)	Total OABSS	
	Score (mean ± SD)	P-value
Postprandial fullness		
Absence (n = 283)	<b>5.24 ± 1.93</b>	<b>0.03</b>
Presence (n = 214)	<b>5.65 ± 2.20</b>	
Early satiation		
Absence (n = 345)	5.32 ± 1.95	0.14
Presence (n = 152)	5.64 ± 2.29	
Epigastric pain		
Absence (n = 405)	5.35 ± 1.98	0.12
Presence (n = 92)	5.72 ± 2.37	
Epigastric burning		
Absence (n = 421)	5.36 ± 2.02	0.13
Presence (n = 76)	5.75 ± 2.26	

Bold values indicate significant associations. OAB, overactive bladder.

These results suggest that concomitant dyspeptic symptoms influence the symptom severity of OAB.

**DISCUSSION**

This large-scale cross-sectional study of a Japanese population revealed a high frequency of overlap between FD and OAB. To our knowledge, this is the first evidence for an independent association between FD and OAB. In IBS patients, many extra-intestinal comorbidities, such as migraine, fibromyalgia, chronic fatigue syndrome, chronic pelvic pain, and depression, are more common.<sup>4,17,18</sup> According to the guidance on IBS from the National Institute for Health and Clinical Excellence (NICE), bladder symptoms are common in people with IBS, and may be used to support the diagnosis of IBS.<sup>19</sup> However, the present study revealed that OAB is a significant co-morbidity not only in IBS, but also in FD.

Overlap between OAB and IBS, diagnosed using the modern criteria, has not been reported previously, although Nickel *et al.*<sup>20</sup> recently documented the overlap of interstitial cystitis/painful bladder syndrome (IC/PBS) with IBS, diagnosed using the Rome III. Although IC/PBS and OAB have similar symptoms, such as urgency, frequency, and nocturia, IC/PBS is differentiated from OAB by the presence of pain. The present study also provides the first evidence for the high prevalence of overlap between IBS and OAB. In addition, our work has revealed that OAB is more prevalent in participants with both IBS and FD than in those with IBS but without FD. Usually, different specialists (e.g., gastroenterologists and urologists) independently treat FD and OAB; this often occurs in the setting of a tertiary care hospital. Both

specialists must recognize the impact of overlap between FD and OAB.

We recently reported that FD patients with concomitant constipation or diarrhea show different characteristics from those without bowel symptoms.<sup>21</sup> We reported that FD patients with bowel symptoms have greater symptom severity than those without bowel symptoms. There were a greater proportion of women, especially with low BMI, in constipation-predominant FD. Alcohol consumption was associated with diarrhea-predominant FD in both genders.<sup>21</sup> The present study revealed that FD participants with IBS-C are likely to have concomitant OAB. Namely, high prevalence of concomitant OAB is thought to be one of the characteristics among constipation predominant FD patients. Previous studies also showed that there is a significant overlap between lower urinary tract symptoms and constipation.<sup>5,22,23</sup> Charach *et al.* reported that medical relief of constipation significantly improves lower urinary tract symptoms in the elderly, and also improves the patient's mood, sexual activity, and quality of life,<sup>24</sup> suggesting that treatment for FD would also improve symptoms of OAB, or vice versa.

We were unable to use the web survey to investigate the mechanism driving the strong association among OAB, FD, and IBS. However, our findings suggest that these conditions may result from common pathogenic mechanisms such as visceral (gastrointestinal and bladder) hypersensitivity, dysfunction of the central or autonomic nervous system, genetic susceptibility, alterations in serotonin (5-HT) signalling and metabolism, and psychological factors including somatization and anxiety. In the present study, participants with early satiation have to urinate more frequently (Table 4), suggesting that impaired gastric accommodation and bladder accommodation might be caused by common mechanisms. Recent studies demonstrated that elevated levels of neurotrophins, namely nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), contribute to bladder overactivity in OAB patients.<sup>25</sup> These factors might also contribute to visceral hypersensitivity in FGIDs.<sup>26</sup> In addition, as gut inflammation is known to cause functional and structural changes in the central nervous system as a result of abnormal afferent input from the gut,<sup>27</sup> it may alter urinary bladder smooth muscle function. Noronha *et al.* reported that a transient colonic inflammatory insult attenuates the amplitude of bladder detrusor muscle contractions in rats.<sup>28</sup> Thus, investigating common mechanisms of OAB and FGIDs might be able to reveal new pathophysiology in these disorders.

Further studies are warranted to define underlying mechanisms.

It is possible that our population was not representative of the general population. As patients who were prescribed any drugs were excluded, some of individuals who have more severe symptoms of FD or OAB may have been filtered out. A potential bias also exists if some individuals do not participate in a web-based panel because of concerns about the technology. However, recent Japanese study to clarify the difference between of the survey methods (electronic survey and postal survey) on the epidemiology of FGID symptoms showed that the proportions of symptom subtypes and the patterns of the overlaps were similar in the two methods, despite the difference in the prevalence.<sup>29</sup> In the same way, it is believed that population biases would not have a large impact on the associations between diseases (odds ratios) shown in the present study.<sup>30</sup>

In conclusion, clinical overlap between OAB and FD is very common. This association was not confounded by coexisting IBS, although concomitant IBS-C increased the risk of OAB among participants with FD. Among participants with OAB, the severity of bladder symptoms was greater in participants with dyspeptic symptoms than without them. These results suggest that a subgroup of patients may show development of OAB and FD through the same pathophysiology, which may lead to the discovery of a novel mechanism in FD. Furthermore, potential OAB symptoms should be considered when evaluating and treating patients with FD.

## FUNDING

This study was supported by a Health and Labour Sciences Research Grant for Research on Health Technology Assessment (Clinical Research Promotion No. 47 to HS), grants from the Smoking Research Foundation (to HS), the Keio Gijuku Academic Development Fund (to HS), Grant-in-Aid for JSPS Fellows DC2 (to JM), a Keio University Grant-in-Aid for Encouragement of Young Medical Scientists (to JM), the Graduate School Doctoral Student Aid Program, Keio University (to JM).

## DISCLOSURE

The authors have no competing interests.

## AUTHOR CONTRIBUTIONS

HS and YF designed the research study, conducted the web survey, and collected the data; JM, HS, KH, SF, and SO analyzed and interpreted the data; JM and HS drafted the article; TH supervised and approved final publication.

## REFERENCES

- 1 Abrams P, Cardozo L, Fall M *et al.* The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. *Urology* 2003; **61**: 37–49.
- 2 Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. *Urology* 2004; **63**: 461–5.
- 3 Whorwell PJ, Lupton EW, Erduran D, Wilson K. Bladder smooth muscle dysfunction in patients with irritable bowel syndrome. *Gut* 1986; **27**: 1014–7.
- 4 Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. *Gut* 1986; **27**: 37–40.
- 5 Coyne KS, Cash B, Kopp Z *et al.* The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. *BJU Int* 2011; **107**: 254–61.
- 6 Aro P, Talley NJ, Agreus L *et al.* Functional dyspepsia impairs quality of life in the adult population. *Aliment Pharmacol Ther* 2011; **33**: 1215–24.
- 7 Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding JE, Talley NJ. Functional dyspepsia impacts absenteeism and direct and indirect costs. *Clin Gastroenterol Hepatol* 2010; **8**: 498–503.
- 8 Brown JS, Vittinghoff E, Wyman JF *et al.* Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. *J Am Geriatr Soc* 2000; **48**: 721–5.
- 9 Gentili A, Weiner DK, Kuchibhatil M, Edinger JD. Factors that disturb sleep in nursing home residents. *Aging* 1997; **9**: 207–13.
- 10 Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD. Urinary incontinence and depression. *J Urol* 1999; **162**: 82–4.
- 11 Macdiarmid SA. Concomitant medications and possible side effects of antimuscarinic agents. *Rev Urol* 2008; **10**: 92–8.
- 12 Homma Y, Yoshida M, Seki N *et al.* Symptom assessment tool for overactive bladder syndrome – overactive bladder symptom score. *Urology* 2006; **68**: 318–23.
- 13 Tack J, Talley NJ, Camilleri M *et al.* Functional gastroduodenal disorders. *Gastroenterology* 2006; **130**: 1466–79.
- 14 Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. *Gastroenterology* 2006; **130**: 1480–91.
- 15 Homma Y, Kakizaki H, Yamaguchi O *et al.* Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. *Urology* 2011; **77**: 60–4.
- 16 Yamaguchi O, Nishizawa O, Takeda M *et al.* Clinical guidelines for overactive bladder. *Int J Urol* 2009; **16**: 126–42.
- 17 Riedl A, Schmidtmann M, Stengel A *et al.* Somatic comorbidities of irritable bowel syndrome: a systematic analysis. *J Psychosom Res* 2008; **64**: 573–82.
- 18 Dotevall G, Svedlund J, Sjodin I. Symptoms in irritable bowel syndrome. *Scand J Gastroenterol Suppl* 1982; **79**: 16–9.
- 19 Dalrymple J, Bullock I. Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. *BMJ* 2008; **336**: 556–8.
- 20 Nickel JC, Tripp DA, Pontari M *et al.* Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. *J Urol* 2010; **184**: 1358–63.
- 21 Matsuzaki J, Suzuki H, Asakura K *et al.* Classification of functional dyspepsia based on concomitant bowel symptoms. *Neurogastroenterol Motil* 2012; **24**: 325–e164.
- 22 Liao YM, Dougherty MC, Biemer PP *et al.* Factors related to lower urinary tract symptoms among a sample of employed women in Taipei. *Neuro-urol Urodyn* 2008; **27**: 52–9.
- 23 Zhu L, Lang J, Liu C, Han S, Huang J, Li X. The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. *Menopause* 2009; **16**: 831–6.
- 24 Charach G, Greenstein A, Rabinovich P, Groskopf I, Weintraub M. Alleviating constipation in the elderly improves lower urinary tract symptoms. *Gerontology* 2001; **47**: 72–6.
- 25 Antunes-Lopes T, Carvalho-Barros S, Cruz CD, Cruz F, Martins-Silva C. Biomarkers in overactive bladder: a new objective and noninvasive tool? *Adv Urol* 2011; **2011**: 382–431.
- 26 Yu YB, Zuo XL, Zhao QJ *et al.* Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. *Gut* 2012; **61**: 685–94.
- 27 Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. *Gastroenterology* 1996; **111**: 1683–99.
- 28 Noronha R, Akbarali H, Malykhina A, Foreman RD, Greenwood-Van Meerveld B. Changes in urinary bladder smooth muscle function in response to colonic inflammation. *Am J Physiol Renal Physiol* 2007; **293**: F1461–7.
- 29 Hongo M. Epidemiology of FGID symptoms in Japanese general population with reference to life style. *J Gastroenterol Hepatol* 2011; **26** (Suppl. 3): 19–22.
- 30 Heiervang E, Goodman R. Advantages and limitations of web-based surveys: evidence from a child mental health survey. *Soc Psychiatry Psychiatr Epidemiol* 2011; **46**: 69–76.

# Transmural Pressure Loading Enhances Gastric Mucosal Cell Proliferation

Hiromasa Nakamizo · Hidekazu Suzuki · Soichiro Miura ·  
Sachiko Mogami · Hiroshi Kishikawa · Hideo Yoshida ·  
Hirofumi Matsui · Toshifumi Hibi

Received: 6 February 2012 / Accepted: 25 April 2012 / Published online: 30 May 2012  
© Springer Science+Business Media, LLC 2012

## Abstract

**Aim** Although increased intraluminal pressure in the stomach due to gastric outlet obstruction or functional gastric motor dysfunction, including gastroparesis, may affect gastric mucosal integrity, the direct effect of mechanical pressure on gastric mucosal cells has not yet been fully investigated. The aims of this study were to determine whether exposure to transmural pressure would affect the proliferation of gastric mucosal cells and to elucidate the intracellular signaling pathways involved.

**Methods** Cellular proliferation and DNA synthesis were evaluated in rat gastric epithelial cells exposed to high transmural pressures. The levels of activation of 3 MAP kinases, ERK, JNK, and p38, were assessed, and the induction of immediate early gene expression was examined. The activation of nuclear factor activator protein-1 (AP-1) was evaluated by an electrophoretic mobility shift assay.

**Results** Exposure to high transmural pressure significantly increased DNA synthesis within 24 h, with the most marked increase observed after exposure to a pressure of 80 mmHg, and this increase was inhibited by the MEK1 inhibitor PD98059. Early activation of ERK kinase, but not

of JNK or p38 kinase, was detected after pressure loading. Early induction of the *c-fos* and *c-myc* genes and activation of the AP-1 transcription factor were also demonstrated within 3 h of exposure to 80 mmHg of pressure.

**Conclusion** Gastric mucosal cell proliferation induced by exposure to high transmural pressure may be related to early activation of ERK, the induction of *c-fos* and *c-myc*, and the activation of AP-1.

**Keywords** Transmural pressure · Cell proliferation · Immediate early response gene (IERG) · Mitogen-activated protein kinase (MAPK) · Gastric motor dysfunction

## Introduction

The gastric mucosa serves as an important barrier to the contents of the gastric lumen, including intraluminal acid, and the epithelium of the gastric mucosa is therefore a site of continual proliferation and differentiation. These processes are regulated by the division of undifferentiated mucous neck cells, and most of the newly produced cells differentiate into surface mucous cells as they migrate rapidly to the surface [1–3]. After injury or ingestion and digestion of food, the functional capacity of the gut can be increased adaptively by increasing the rate at which the gastric epithelium is renewed [4, 5]. Although the precise mechanisms regulating the normal and adaptive growth of the gastric epithelium remain unknown, not only neural mechanisms [6], hormones [7, 8], and growth factors, but also mechanical stimuli such as intragastric pressure or volume overload, are thought to be involved.

Specifically, the pyloric canal is characterized by hypertrophic muscle up to 6-mm thick in patients with infantile hypertrophic pyloric stenosis (IHPS) [9]. In these

H. Nakamizo · H. Suzuki (✉) · S. Mogami · H. Kishikawa ·  
H. Yoshida · T. Hibi  
Division of Gastroenterology and Hepatology, Department  
of Internal Medicine, Keio University School of Medicine,  
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan  
e-mail: hsuzuki@a6.keio.jp

S. Miura  
Second Department of Internal Medicine,  
National Defense Medical College, Tokorozawa, Japan

H. Matsui  
Division of Clinical Medicine, Faculty of Medical Sciences,  
University of Tsukuba, Tsukuba, Japan

cases, the canal lumens are filled with compressed and redundant mucosa, which protrudes into the gastric antrum because the rigid antropyloric canal is unable to accommodate it [10]. The decreased diameter of the canal lumen in IHPS (3 mm or less) makes the intraluminal pressure extraordinarily high; this could account for the accompanying mucosal hypertrophy, which typically equals or far exceeds the muscle thickness. We recently reported that surgically induced rat gastric outlet obstruction resulted in an increased wet weight of the stomach as well as remarkable hyperplasia of the gastric muscle layers with enhanced levels of fasting plasma ghrelin and expression of the c-kit, a marker for interstitial cells of Cajal, choline acetyltransferase and stem cell factor, a c-kit ligand [6], suggesting that the mechanism by which narrowing of the pyloric canal promotes cell proliferation may involve elevated intragastric pressure [8]. Even without the persistently high pressure loading possibly encountered in IHPS or gastric outlet obstruction, in functional dyspepsia (FD), especially postprandial distress syndrome (PDS), based on the Rome III classification [11, 12], the deregulated antral peristalsis or disturbed fundic accommodation may lead to the development of intragastric pressure after food intake is intermittently enhanced, possibly to supraphysiological levels, leading to possible high transmural pressure overloading at the gastric wall.

The expression of genes encoding regulators of gastric function is modulated over a period of several hours by the gastric contents and also changes rapidly with changes in the digestive state. For example, antral gastrin mRNA levels in rats are significantly elevated relative to fasting levels 1–2 h after refeeding, while the somatostatin mRNA levels are depressed at this time point [13]. The factors mediating these feeding-induced changes in gene expression are not yet clear, but the rapidity of the onset of these changes suggests the involvement of immediate early gene expression and mitogen-activated protein kinase (MAPK) activation. Two aspects of feeding that might trigger the expression of immediate early genes are physical distension of the stomach and chemical stimulation of the mucosa, and Dimaline et al. [14] have shown that distension of gastric mucosa can itself induce the expression of *c-fos* and *c-myc*.

The mean intragastric pressure produced by fundic waves in healthy dogs has been shown to be >53 cm H<sub>2</sub>O (39 mmHg) [15]. Thomas and Kelly classified changes in the intraluminal pressure recorded from the proximal gastric pouch into several types of waves and showed that type III waves (fundic waves) were contractions with amplitudes in excess of 60 cmH<sub>2</sub>O (44 mmHg) [16]. The characteristic contractions of the distal stomach represent peristaltic waves. Human antral contractions during fasting produce intraluminal pressure changes ranging from a few to over 100 cmH<sub>2</sub>O (74 mmHg) in amplitude and from 1 to

4 s in duration [17], and such intraluminal pressures influence the biological activity of the gastric mucosa. According to ambulatory gastrojejunal manometry data [18], antral motor activity in humans has amplitude of about 50 mmHg with a duration of 4.7–4.9 s. We have recently demonstrated that exposure to transmural pressure induces cell proliferation and DNA synthesis in cultured intestinal epithelial cells, suggesting that mechanical pressure is involved in the regulation of mucosal remodeling in the intestine [19]. In the present study, the term “remodeling” was used to describe the enhancement of cell proliferation in response to transmural pressure, resulting in hyperplastic changes of the entire gastric wall, a totally different term from restitution. Intraluminal pressure, may also be involved in mucosal remodeling of the gastric mucosa, but little is known about the mechanisms underlying pressure-induced growth of gastric mucosal epithelial cells.

In the model of shear stress loading to vascular endothelial cells, the molecular mechanisms that transduce physical stress into gene transcriptional changes have been well investigated. Some of the endothelial second messenger activities associated with this transduction is ion channel activation, stimulation of protein kinase C (PKC) activity, and activation of MAPK pathways [20–22]. Downstream targets of activated MAPK pathways include immediate early response genes (IERG), such as *c-myc* [23], *c-fos* [24] and *c-jun* [25]. These IERGs have been shown to respond to changes in shear stress in endothelial cells [26]. c-Fos/c-Jun heterodimers (assembled by leucine zipper formation) bind primarily to the nuclear factor activator protein-1 (AP-1) site, where they activate transcription [27]. The phosphorylation and activation of these transcription factors induce immediate early gene expression with subsequent entry of the cells into the cell cycle.

In the present study, we first investigated whether exposure of gastric mucosal cells to increased transmural pressure affected their proliferation. Having established that it did, we attempted to investigate the mechanisms by which mechanical pressure might affect the intracellular signaling pathways leading to cell growth. Our results revealed that in cultured gastric epithelial cell lines, mechanical stimulation activates MAPK pathways, induces nuclear proto-oncogenes, and stimulates the formation of AP-1-DNA complexes.

## Materials and Methods

### Pressure Loading and Evaluation of Cell Proliferation

A gastric mucosal epithelial cell line (RGM-1) established from the gastric mucosa of adult Wistar rats [28] was

obtained from Riken Cell Bank (Tsukuba, Japan). The stock cultures were grown at 37 °C under 5 % CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM) containing 5 % fetal bovine serum (FBS), 10 µg/ml insulin, 50 U/ml penicillin, 50 U/ml streptomycin, and 4 mM glutamine. The pressure-loading apparatus was set up as previously described [19]. The cell culture plates were placed in an acrylic flask from which the upper panel had been removed, and the flask was then resealed with a rubber seal and tightly clamped. The rubber seal was pierced by a needle connected to tubing attached to a 3-way rotary valve, a sphygmomanometer, and a pressure valve. Compressed helium was pumped into the flask to raise the internal pressure; none of the prepacked room air was released during this process. The flask was kept at 37 °C throughout pressurization.

Cells were cultured in 96-well multiwell plates (200 cells per well) in DMEM containing 5 % FBS. The cells were allowed to attach to their substrates for 24 h, and then the culture medium was changed to DMEM containing 0.1 % FBS for the growth experiments. Four and 48 h after each treatment, the numbers of cells were determined as follows. At the end of the incubation period, the rate of reduction of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salts] to formazan was assessed using the CellTiter 96 AQ non-radioactive cell proliferation assay kit (Promega Co., Madison, WI, USA) and the absorbance of formazan at 490 nm was measured.

DNA synthesis was assessed with an immunocytochemical assay kit that uses monoclonal anti-bromodeoxyuridine (BrdU) antibody to detect the incorporation of BrdU into the cellular DNA (RPN 210; Amersham Corp., Tokyo, Japan) [19]. Bound antibody was detected using a peroxidase-conjugated antibody to mouse IgG<sub>2a</sub> and a peroxidase substrate, yielding a soluble green reaction product proportional to the amount of BrdU incorporated.

The number of cells with membrane barrier dysfunction was determined using the cationic fluorescence dye propidium iodide (PI, Molecular Probes, Inc., Eugene, OR, USA).

#### MAPK Inhibition and Determination of MAPK-Associated Phosphorylation

The effect of inhibition of MAPK on pressure-induced cell proliferation was assessed by adding the selective MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA, USA) [29] to the culture medium. The agent was added just before the cells were pressure-loaded.

MAPK activity was assessed using a p42/44 MAPK enzyme assay system (Amersham International plc, Buckinghamshire, UK), which measures incorporation of

<sup>32</sup>[P]-ATP into a synthetic peptide substrate that is highly selective for p44/42 MAPK. MAPK activity was assessed by counting the radioactivity with a scintillation counter. The peptide used in this assay is based on the Thr<sup>669</sup> phosphorylation site of the epidermal growth factor (EGF) receptor and has been modified to contain only one phosphorylation site.

The activity of the MAP kinases extracellular signal-regulated kinase (ERK) was assessed by western blot analysis using a p44/42 MAPK assay kit (New England Biolabs Inc., Beverly, MA, USA). The activity of the c-Jun NH<sub>2</sub>-terminal kinase (JNK) was assessed by western blot analysis using a SAPK/JNK assay kit (New England Biolabs Inc., Beverly, MA, USA). The activity of the p38 MAP kinases was assessed by western blot analysis using a p38 MAP kinase assay kit (New England Biolabs Inc., Beverly, MA). The RGM-1 cells (1 × 10<sup>6</sup>) in the flasks were exposed to a pressure of 80 mmHg for 48 h, washed with PBS, and lysed in ice-cold cell lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid [EDTA], 1 mM EGTA, 1 % Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, and 1 µg/ml leupeptin) with 1 mM phenylmethylsulfonyl fluoride (PMSF). The lysates were clarified by microcentrifugation and each MAPK activity was assessed according to the manufacturer's protocol. Briefly, p44/42 and p38 MAPK were immunoprecipitated using Sepharose bead conjugated phospho-specific anti-p44/42 MAPK monoclonal antibody or agarose hydrazide beads conjugated phospho-p38 MAP Kinase (Thr180/Tyr182) monoclonal antibody for 4 h. The resulting immunoprecipitants were incubated for 30 min with Elk-1 or ATF-2 fusion protein in the presence of 200 µM adenosine triphosphate (ATP) and kinase buffer (25 mM Tris pH 7.5, 5 mM β-glycerophosphate, 2 mM dithiothreitol [DTT], 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, and 10 mM MgCl<sub>2</sub>) in order to allow the immunoprecipitated active MAPK to phosphorylate each substrate. For assessing JNK activity, the lysates were incubated with GST-c-Jun fusion bound to glutathione agarose beads in the presence of 200 µM ATP. The phosphorylation reactions were terminated by mixing the lysate samples with 25 µl each of 3 × sodium dodecyl sulfate (SDS) sample buffer (187.5 mM Tris-HCl pH 6.8), boiled for 5 min, and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred to nitrocellulose membranes and probed with the appropriate antibodies. The western blots were developed as follows: the membranes were blocked with a blocking buffer (1 × Tris-buffered saline [TBS] with 0.1 % Tween-20 and 5 % w/v nonfat dry milk) and incubated with primary antibody (phospho-specific anti-Elk-1 antibody, phospho-c-Jun [Ser63] antibody, phospho-ATF-2 [Thr71] antibody [1:1,000]) overnight and then with horseradish

peroxidase (HRP)-conjugated anti-rabbit secondary antibody (1:2,000) or HRP-conjugated anti-biotin antibody (1:2,000) for 1 h. Finally, the membranes were incubated with 10 mM 1× LumiGLO (20× LumiGLO, 20× peroxide, and water) for 1 min and the bands visualized by chemiluminescence.

### PCR Amplification of IREGs

Total RNA was isolated from RGM-1 cells using RNazol (Biotex, Houston, TX, USA). The cells were lysed by the addition of 1.0 ml of RNazol to each dish, and the RNA was isolated and extracted according to the manufacturer's protocol. Briefly, the RNA was extracted with chloroform, precipitated with isopropanol, and then washed with 70 % ethanol. The concentration of the extracted RNA was calculated by measuring the optical density at 260 nm, and the 260/280 ratio was >1.9 for all RNA preparations. The RNA quality was assessed based on the integrity of the 28S and 18S bands and the absence of degradation during agarose gel electrophoresis.

Aliquots of RNA (5 µg) were reverse-transcribed using 1st Strand cDNA Synthesis Kit (Stratagene, La Jolla, CA). In brief, 5 µg of RNA in 38 µl of diethyl pyrocarbonate-treated water was mixed with 0.3 µg of oligo (dT), heated at 65 °C for 5 min, and then cooled slowly to room temperature. The following reagents were then added to the tubes: 5 µl of 10× concentrated synthesis buffer (final concentrations, 10 mM Tris-HCl pH 8.3, 50 mM KCl, and 1.5 mM MgCl<sub>2</sub>), 1 µl of RNase block (40 U/µl), 2 µl of 100 mM dNTPs, and 1 µl of Moloney murine leukemia virus reverse transcriptase (50 U/µl). The reaction mixture was incubated for 1 h at 37 °C and the reaction was then terminated by incubating the tubes at 90 °C for 5 min and placing them on ice for 10 min. The tubes were stored at -80 °C pending PCR. PCR was performed using the Takara Taq kit (recombinant Taq DNA polymerase; Takara Biochemicals, Tokyo, Japan) with rat-specific primers prepared on a DNA synthesizer (Sawady Technology, Tokyo, Japan). The sequences of the primers designed to amplify the cDNA sequences of rat *c-fos*, *c-myc*, and *c-jun* were as follows:

<i>c-fos</i>	Sense	5'-GGTCATCGGGGATCTTGC-3'	511 bp
	Antisense	5'-GGGCTCTCCTGTCAAC-3'	
<i>c-myc</i>	Sense	5'-AGGTCCGAGTCAGGGTCATC-3'	455 bp
	Antisense	5'-AACTGTTCTCGCCGTTTCCT-3'	
<i>c-jun</i>	Sense	5'-CGACCTTCTACGACGATGCC-3'	258 bp
	Antisense	5'-TCGGTGTAGTGGTGATGTGC-3'	

The predicted lengths of the cDNA amplification products were 511 bp for *c-fos*, 455 bp for *c-myc*, and 258 bp for *c-jun*. The PCR was initiated by adding 2 µl of reverse transcriptase products to a PCR master mix containing 10× PCR reaction buffer diluted to final concentrations of 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 2.5 U of recombinant Taq DNA polymerase, 50 pM each of the primers, and 200 µM dNTPs. The tubes were placed in a Programmed Tempcontrol system (Applied Biosystems, Tokyo, Japan) that was programmed as follows: incubation for 3 min at 94 °C for initial denaturation, followed by 35 cycles of denaturation at 95 °C for 1 min, annealing at 55 °C for 1 min, and extension at 72 °C for 2 min for *c-fos*, 25 cycles of denaturation at 94 °C for 0.5 min, annealing at 52 °C for 1 min, and extension at 74 °C for 1 min for *c-myc*, or 35 cycles of denaturation at 94 °C for 1 min, annealing at 56 °C for 1 min (annealing), and extension at 72 °C for 3 min for *c-jun*, followed by a final extension at 72 °C for 7 min for all products. The PCR products were size-fractionated by agarose gel electrophoresis, stained with ethidium bromide, and then visualized with an ultraviolet transilluminator.

### Immunofluorescence Staining for c-Myc and c-Fos Proteins

The distributions of the c-Fos and c-Myc proteins in the cultured cells were determined by immunofluorescence staining using specific monoclonal antibodies. Cells were cultured in 8-well Lab Tek tissue culture chambers, washed three times with PBS (pH 7.4), and fixed with 4 % paraformaldehyde for 30 min. The fixed cells were washed three more times with PBS and then incubated for 5 min in PBS containing 0.1 % Triton X 100. The permeabilized cells were rinsed with PBS and incubated at 4 °C for 60 min with PBS containing 1 % BSA, a mouse monoclonal antibody (IgG<sub>2a</sub>) directed against c-Fos (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and a rabbit polyclonal antibody (IgG) directed against c-Myc (Santa Cruz Biotechnology, Inc.). After hybridization, the cells were washed three times with PBS containing 1 % BSA and incubated at room temperature for 30 min in the dark with an FITC-conjugated rabbit anti-mouse IgG antibody (20 µg/ml, Chemicon International, Inc., Temecula, CA, USA) in PBS containing 1 % BSA. The cells were then washed again, mounted on the chamber slide, and covered with a non-fluorescent cover slip. Confocal imaging was performed with an MRC 600 confocal microscope (Bio Rad, Watford, UK) mounted on an inverted-type fluorescence microscope (Diaphot, TMD-2S, Nikon, Tokyo, Japan) with a 63× oil immersion lens. A multiple-line argon-ion laser beam (25 mW) was used for excitation at 488 nm.

## DNA-Binding Activity of AP-1

The DNA-binding activity of AP-1 was determined by electrophoretic mobility shift assay (EMSA) using a FITC-labeled consensus AP-1 oligonucleotide as the probe. Subconfluent RGM-1 cells ( $1 \times 10^6$ ) were exposed to a pressure of 80 mmHg for 1–2 h. The proteins were then extracted as follows. The cells were washed with PBS, collected by scraping with a cell scraper, and homogenized at 4 °C in Buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM PMSF, 1 mM DTT, and 1 µg/ml each of antipain, chymostatin, leupeptin, and pepstatin A). The suspension was then centrifuged at 11,000 rpm for 2 min and the supernatant removed. The precipitate was homogenized again in Buffer A and centrifuged at 11,000 rpm for 2 min and the supernatant removed. This precipitate was then homogenized for 40 min at 4 °C in Buffer C (20 mM HEPES pH 7.9, 10 mM KCl, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 0.5 mM PMSF, 1 mM DTT, and 1 µg/ml each of antipain, chymostatin, leupeptin, and pepstatin A), and the suspension was centrifuged at 15,000 rpm for 10 min and the precipitate removed. The protein concentrations of the extracts were measured, and the extracts were stored at –70 °C until the gel shift assays with FITC-labeled AP-1 oligonucleotide (5'-CGCTTGATGAGT-CAGCCGGAA-3') were performed. In brief, 20 µg of extracted protein was incubated with AP-1 oligonucleotide (1 ng) for 45 min at room temperature, mixed with 50 % sucrose (5 µl), and subjected to electrophoresis at 160 V on nondenaturing 5 % polyacrylamide gels for 1 h. The fluorescence intensities of the bands in the gels were quantified using a fluorescence laser scanning system equipped with a computer-assisted image analyzer (FluorImager 575; Molecular Dynamics, Sunnyvale, CA, USA).

## Statistical Analysis


All results were expressed as means  $\pm$  standard errors of the mean (SEM), and differences between groups were evaluated by one-way analysis of variance (ANOVA) and Fisher's post hoc test. Statistical significance was set at  $P < 0.05$  for all tests.

## Results


### Pressure-Induced Cell Proliferation and Inhibition Studies

RGM-1 cells exhibited proliferation in response to exposure to high transmural pressure without shear stress. Exposure of the cells to high transmural pressures in the range of 40–120 mmHg resulted in significantly increased

cell numbers after treatment for 48 h but not 24 h (Fig. 1). The greatest cell number was observed after treatment at a pressure of 80 mmHg and was about 1.8 times ( $182 \pm 9\%$ ,  $P < 0.05$ ) than that of the control (0 mmHg). Light microscopy and trypan blue exclusion assays at the end of the experiments showed that the cells were intact, and the number of detached cells was negligible even after exposure to pressures up to 160 mmHg (data not shown). Examination of BrdU incorporation into the cellular DNA revealed a pressure-induced increase in DNA synthesis even 24 h after the beginning of the high transmural pressure treatment (Fig. 2); therefore, the enhanced DNA synthesis preceded the increased cell numbers.



**Fig. 1** Effect on cell proliferation of exposure of RGM-1 cells to high transmural pressures. RGM-1 cells in medium containing 0.1 % FBS were subjected to high transmural pressures, and the cell numbers were counted after exposure for 24 and 48 h. Values are expressed as the mean  $\pm$  standard error of the mean (SEM) ( $n = 6$ ) % increase relative to the 0 mmHg control value. \* $P < 0.05$  versus without additional pressure (0 mmHg)



**Fig. 2** Effect on DNA synthesis of exposure of RGM-1 cells to high transmural pressures. RGM-1 cells in medium containing 0.1 % FCS were subjected to high transmural pressures, and DNA synthesis was determined after exposure for 24 h. Values are expressed as the mean  $\pm$  SEM ( $n = 6$ ) % increase relative to the 0 mmHg control value. \* $P < 0.05$  versus without additional pressure (0 mmHg)




### Activation of MAPK by Pressure Loading of Cells


MAPK enzyme activity was evaluated by measuring the incorporation of  $^{32}\text{P}$ -ATP into a synthetic peptide substrate highly selective for p44/p42 MAP kinase (Fig. 3). The MAPK assay showed that the radioactivity count from phosphorylation of the Thr<sup>669</sup> phosphorylation site of the EGF receptor was significantly increased by exposing the cells to a transmural pressure of 80 mmHg for 6 h.

Western blot analysis was also used to evaluate MAPK-associated phosphorylation of the Elk-1, c-Jun, AFT-2 substrate after subjecting the cells to a transmural pressure of 80 mmHg. Figure 4 shows the pressure-induced increase in phosphorylation corresponding to activation of the MAP kinases (Fig. 4). By normalizing each of the band densities for the control (0 h) using ImageJ densitometry, we observed that although the ERK-associated phosphorylation increased to 9.4-fold at 3 h and 7.0-fold at 6 h after loading of transmural pressure at 80 mmHg, no significant enhancement of JNK-associated phosphorylation (0.9-fold at 3 h and 0.8-fold at 6 h) or p38-associated phosphorylation (0.6-fold at 3 h and 0.8-fold at 6 h) was detected after transmural pressure loading (Fig. 4).


Then we used PD98059, a MEK1 inhibitor, prior to subjecting cells to a transmural pressure of 80 mmHg for 48 h, in order to specifically attenuate ERK-dependent cell proliferation (Fig. 5). PD98059 (10  $\mu\text{M}$ ) significantly inhibited the induction of cell proliferation due to exposure to transmural pressure. Treatment with PD98059 or vehicle alone without transmural pressure for 48 h did not suppress cell proliferation (vehicle,  $106 \pm 2.03\%$  and PD98059,  $98.7 \pm 2.46\%$  of control).



**Fig. 3** Effect on MAPK activation in RGM-1 cells of exposure to high transmural pressure (80 mmHg). MAPK enzymatic activity levels in cells exposed to pressure for 0, 3, or 6 h were assessed by measuring the incorporation of  $^{32}\text{P}$ -ATP into a synthetic peptide substrate selective for p44/42 MAP kinase. Values are expressed as the mean  $\pm$  SEM (of 6 experiments) % increase relative to the 0 mmHg control value. \* $P < 0.05$  versus controls (0 h)




**Fig. 4** Western blot analysis of MAPK-associated phosphorylation of the Elk-1, c-Jun and ATF-2 substrate in RGM-1 cells exposed to a transmural pressure of 80 mmHg for 0, 3, or 6 h. The pressure-induced increase in the phosphorylation of each substrate, corresponding to the activation of MAP kinases (ERK, JNK and p38), was determined. Representative results from four different experiments are shown



**Fig. 5** Effect of a MAPK inhibitor (PD98059) on the pressure-induced proliferation of RGM-1 cells. PD98059 (10  $\mu\text{M}$ ) was added to the culture medium immediately prior to pressure loading. The cell numbers were then determined after exposure to a transmural pressure of 80 mmHg for 48 h. Values are expressed as the mean  $\pm$  SEM ( $n = 6$ ) % increase relative to the 0 mmHg control value. \* $P < 0.05$  versus without additional pressure (0 mmHg). # $P < 0.05$  versus pressure alone

### mRNA Expression of IREGs

RT-PCR showed that RGM-1 cells expressed *c-fos*, *c-myc*, and *c-jun* mRNA, producing band sizes of 511, 455, and 258 bp, respectively (Fig. 6). Exposing the cells to a transmural pressure of 80 mmHg for 3 h markedly increased the level of *c-fos* mRNA to 8.6-fold of that in the control cells (0 mmHg). The expression level of *c-fos* mRNA remained 1.5-fold higher in the pressure-treated cells than in the control cells after treatment for 6 h. The



**Fig. 6** Expression of *c-fos*, *c-myc*, and *c-jun* mRNA in RGM-1 cells exposed to a transmural pressure of 80 mmHg for 0, 1, 3, or 6 h, as determined by RT-PCR. Expression of *c-fos*, *c-myc*, and *c-jun* mRNA in RGM-1 cells is shown by bands at 511, 455, and 258 bp, respectively. Representative results from four experiments are shown


level of *c-myc* mRNA in the RGM-1 cells was markedly increased by 2.2-fold after 1 h of exposure to a transmural pressure of 80 mmHg, although the levels had fallen again after 3 and 6 h. No significant increase in the expression of *c-jun* mRNA (0.8-fold at 1 h, 0.9-fold at 3 h, and 0.9-fold at 6 h) was observed after pressure loading of these cells.

### Immunofluorescence Staining for c-Fos and c-Myc Proteins

Increased expression of c-Fos and c-Myc proteins was detected by immunofluorescence staining and laser confocal microscopy (Fig. 7). In control cells not subjected to increased pressure, FITC-labeled anti-c-Fos and c-Myc antibodies were predominantly observed in the cytosol. Three hours after the cells were subjected to a transmural pressure of 80 mmHg, strong induction of the c-Fos and c-Myc proteins was evident not only in the cytosol but also in the nuclei of the cells. Although the total expression of c-Fos and c-Myc appeared to be increased by a transmural pressure of 120 mmHg, as compared to 80 mmHg, the nuclear localization of c-Fos and c-Myc was higher at 80 mmHg than 120 mmHg, suggesting that nuclear localization of c-Fos and c-Myc may be able to detect enhanced cell proliferation and DNA synthesis. At the 3-h time point, nuclear staining of c-Myc was higher than that of c-Fos, possibly in line with the earlier response of *c-myc* assessed by RT-PCR in Fig. 6.

### Activation of Nuclear Factor AP-1

Members of the c-Fos and c-Jun protein family dimerize to form AP-1 transcription factor complexes that regulate the expression of other genes. To determine whether pressure loading increased AP-1 binding activity in RGM-1 cells,




**Fig. 7** Induction of c-Fos and c-Myc protein expression in RGM-1 cells exposed to high transmural pressures, as detected by immunofluorescence staining and laser confocal microscopy. Three hours after exposure to a transmural pressure of 80 or 120 mmHg, strong

induction of the c-Fos and c-Myc proteins was observed not only in the cytosol but also in the nuclei of the cells. Representative results from three experiments are shown

we performed an electrophoretic mobility gel shift assay using an oligonucleotide probe containing an AP-1-binding site. Figure 8 shows activation of AP-1 in RGM-1 cells exposed to a transmural pressure of 80 mmHg; in contrast, control extracts contained little activated AP-1 (Fig. 8, left lane). Increased amounts of activated AP-1 were evident 1 and 3 h after the cells were subjected to a transmural pressure of 80 mmHg (middle and right lanes). The degrees of AP-1 activation after 1 and 2 h appeared to be almost equal.

## Discussion

In the present study, we demonstrated that exposure to transmural pressure induced gastric epithelial cells to proliferate and that this proliferation might be due to activation of exclusively ERK, but not JNK and p38, and IERGs such as *c-fos* and *c-myc*. Our results indicate that transmural pressure may be involved in the remodeling of gastric wall. Exposure to pressures >40 mmHg significantly induced proliferation of the RGM-1 cells. Intra-gastric pressures have been reported to reach over 60 cmH<sub>2</sub>O (44 mmHg) in the proximal gastric pouch during fundic



**Fig. 8** AP-1-DNA binding activity as determined by electrophoretic mobility shift assay (EMSA) using a FITC-labeled consensus AP-1 oligonucleotide as the probe. This fluorograph from an RGM-1 cell gel-shift study demonstrates AP-1-DNA binding activity in cells exposed to a transmural pressure of 80 mmHg. An extract of RGM-1 cells not exposed to additional pressure (0 h) was used as a control. An increase in the amount of activated AP-1 is evident 1 and 3 h after exposure of the cells to a transmural pressure of 80 mmHg (lanes 1h and 3h)

waves and to over 100 cmH<sub>2</sub>O (74 mmHg) in the distal stomach during antral peristaltic waves [17].

Our results indicate that gastric epithelial cell growth can be promoted by physiological levels of intragastric pressure produced by gastric peristaltic waves. Although continually high transmural pressures could be encountered in IHPS due to the narrowed antropyloric canal, resulting in the extraordinary levels of mucosal hypertrophy [10], the present results are not applicable to physiological conditions, in which the gastric mucosa is subjected only intermittently, rather than continuously, to high transmural pressures. The growth of gastric epithelial cells under periodic pressure loading, mimicking physiological conditions, should therefore be investigated as well. For example, in FD, especially PDS based on the Rome III classification [11, 12], dysmotility of the gastroduodenum is a major pathogenetic factor. The weakened antral peristalsis or disturbed fundic accommodation may lead to the development of intragastric pressure after food intake is intermittently enhanced, possibly to supraphysiological levels, leading to high transmural pressure overloading to the gastric wall.

We found that exposure to a pressure of 160 mmHg inhibited cell proliferation, suggesting that epithelial cell growth might be attenuated by supraphysiological transmural pressures. Exposure to a pressure of 120 mmHg was associated with an increase in the number of gastric cells after 48 h; however, no increase in DNA synthetic activity was noted after 24 h. These results are consistent with early activation of immediate early genes or AP-1 after 3–6 h, and we suspect that the bulk of the DNA synthesis may have occurred before 24 h had elapsed.

The MAPKs are part of a well-characterized protein kinase system that has been shown to mediate cellular responses to physical forces, including stretching and osmotic stress [30, 31]. Activation of the MAPK signal transduction pathway seems to be especially important in the healing of injured gastrointestinal mucosa. Pai et al. recently reported that activation of an EGF-receptor-ERK signal-transduction pathway may play an important role in the healing of experimentally-produced gastric ulcers [32, 33]. Recent in vitro studies have also shown that injury to intestinal epithelial cells activates the Raf-1, ERK1, ERK2, and JNK1 [34]. In our present study, western blot analysis showed that ERK kinase was activated in RGM-1 cells 3 h after the onset of pressure loading and remained activated for up to 6 h. In contrast, JNK and p38 kinases were not significantly activated by pressure loading. In contrast, MacKenna et al. [21] reported that while ERK and JNK1 were rapidly activated in rat cardiac cells by 4 % static biaxial stretch in an apparently integrin-mediated manner, p38 was not activated by this 4 % static biaxial stretch. These results showed that the MAPK family kinases do not necessarily act in the same fashion in response to physical-force overload in line with the present results.

Products of the *c-fos*, *c-myc*, and *c-jun* genes are thought to be important in cell proliferation, and regulation of their expression levels is therefore crucial. In our previous study using intestinal epithelial cells (IEC-6 cells), we demonstrated that transmural pressure loading promoted the expression of *c-fos* and *c-myc*, but not *c-jun*, perhaps as a result of MAPK activation [35]. Recently, gastric myenteric cellular c-Fos expression has been shown to be enhanced in response to stresses such as the administration of a thyrotropin-releasing hormone agonist, suggesting a possible contribution of gastric transmural pressure overload. It has been shown that feeding a liquid diet to fasting rats induces the expression of c-Fos in the brainstem [36], an area associated with the responses to gastric distension [37], possibly linked to the genesis of accommodation. Dimaline et al. [14] reported induction of c-Fos expression in the gastric myenteric neurons in response to physiological stretching of the stomach wall. They therefore speculated that supraphysiological stretching of the stomach wall might also induce expression of c-Jun and c-Myc. Activation of JNK leads to phosphorylation of c-Jun, a component of the transcription factor AP-1 that in turn is an important mediator of cell growth regulation by trophic peptides [38]. Activation of AP-1-mediated transcription and cell growth regulation commonly involves rapid and transient induction of mRNA and protein expression of c-Fos and c-Jun [38, 39]. AP-1 was reported to form complexes with DNA when cultured vascular endothelial cells were subjected to shear stress [40]. In the present study, we demonstrated that AP-1 formed complexes with DNA when gastric epithelial cells were subjected to transmural pressure. As a hypothesis, transmural pressure might enhance ERK-associated phosphorylation by MEK1. Activated ERK then phosphorylates c-Myc, and phosphorylated c-Myc translocates into the nucleus and enhances *c-fos* transcription. c-Fos might then bind to DNA as transcription factor AP-1, resulting in enhancement of cell proliferation.

An understanding of the control of the responses to pressure loading in gastric epithelial cells may provide novel insights into the regulation of gastric epithelial remodeling under the conditions of long-term deregulation of gastric motor function [12] that may be encountered in patients with (IHPS) [10] or severe gastric motor dysfunction including gastroparesis.

In conclusion, gastric mucosal proliferation was enhanced by transmural pressure loading through the AP-1 mediated induction of early genes such as *c-fos* and *c-myc* and early activation of ERK.

**Acknowledgments** This study was supported in part by a Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (no. 22300169, to HS), a Health and Labour Sciences Research Grant for Research on Health Technology Assessment (Clinical Research Promotion no. 47 to HS), a grant from the

Smoking Research Foundation (to HS), the Keio Gijuku Academic Development Fund (to HS) and National Defense Medical College.

**Conflict of interest** None.

## References

- Karam SM, Leblond CP. Dynamics of epithelial cells in the corpus of the mouse stomach. II. Outward migration of pit cells. *Anat Rec.* 1993;236:280–296.
- Suzuki H, Minegishi Y, Nomoto Y, et al. Down-regulation of a morphogen (sonic hedgehog) gradient in the gastric epithelium of *Helicobacter pylori*-infected Mongolian gerbils. *J Pathol.* 2005; 206:186–197.
- Minegishi Y, Suzuki H, Arakawa M, et al. Reduced Shh expression in TFF2-overexpressing lesions of the gastric fundus under hypochlorhydric conditions. *J Pathol.* 2007;213:161–169.
- Lacy ER, Ito S. Rapid epithelial restitution of the rat gastric mucosa after ethanol injury. *Lab Invest.* 1984;51:573–583.
- Tsuji M, Kawano S, Tsuji S, et al. Cell kinetics of mucosal atrophy in rat stomach induced by long-term administration of ammonia. *Gastroenterology.* 1993;104:796–801.
- Hirata K, Suzuki H, Nishizawa T, et al. Contribution of efflux pumps to clarithromycin resistance in *Helicobacter pylori*. *J Gastroenterol Hepatol.* 2010;25:S75–S79.
- Mogami S, Suzuki H, Fukuhara S, Matsuzaki J, Kangawa K, Hibi T. Reduced ghrelin production induced anorexia after rat gastric ischemia and reperfusion. *Am J Physiol Gastrointest Liver Physiol.* 2012;302:G359–64.
- Iwasaki E, Suzuki H, Masaoka T, et al. Enhanced gastric ghrelin production and secretion in rats with gastric outlet obstruction. *Dig Dis Sci.* 2011;57:858–864.
- Hernanz-Schulman M, Sells LL, Ambrosino MM, Heller RM, Stein SM, Neblett WW III. Hypertrophic pyloric stenosis in the infant without a palpable olive: accuracy of sonographic diagnosis. *Radiology.* 1994;193:771–776.
- Hernanz-Schulman M. Infantile hypertrophic pyloric stenosis. *Radiology.* 2003;227:319–331.
- Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. *Gastroenterology.* 2006;130:1466–1479.
- Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. *J Gastroenterol.* 2006;41:513–523.
- Wu SV, Sumii K, Tari A, Mogard M, Walsh JH. Regulation of gastric somatostatin gene expression. *Metabolism.* 1990;39:125–130.
- Dimaline R, Miller SM, Evans D, Noble PJ, Brown P, Poat JA. Expression of immediate early genes in rat gastric myenteric neurones: a physiological response to feeding. *J Physiol.* 1995;488:493–499.
- Lind JF, Duthie HL, Schlegel JF, Code CF. Motility of the gastric fundus. *Am J Physiol.* 1961;201:197–202.
- Thomas PA, Kelly KA. Hormonal control of interdigestive motor cycles of canine proximal stomach. *Am J Physiol.* 1979;237: 191–197.
- Kelly KA. Gastric motility after gastric operations. *Surg Annu.* 1974;6:103–123.
- Wilmer A, Van Cutsem E, Andrioli A, Tack J, Coremans G, Janssens J. Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying. *Gut.* 1998;42:235–242.
- Hirokawa M, Miura S, Shigematsu T, et al. Pressure stimulates proliferation and DNA synthesis in rat intestinal epithelial cells. *Life Sci.* 1997;61:667–672.

20. Jo H, Sipos K, Go YM, Law R, Rong J, McDonald JM. Differential effect of shear stress on extracellular signal-regulated kinase and N-terminal Jun kinase in endothelial cells. Gi2- and Gbeta/gamma-dependent signaling pathways. *J Biol Chem.* 1997;272:1395–1401.
21. MacKenna DA, Dolfi F, Vuori K, Ruoslahti E. Extracellular signal-regulated kinase and c-jun NH2-terminal kinase activation by mechanical stretch is integrin-dependent and matrix-specific in rat cardiac fibroblasts. *J Clin Invest.* 1998;101:301–310.
22. Yamazaki T, Tobe K, Hoh E, et al. Mechanical loading activates mitogen-activated protein kinase and S6 peptide kinase in cultured rat cardiac myocytes. *J Biol Chem.* 1993;268:12069–12076.
23. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. *J Biol Chem.* 1993;268:14553–14556.
24. Chen RH, Abate C, Blenis J. Phosphorylation of the c-fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. *Proc Natl Acad Sci USA.* 1993;90:10952–10956.
25. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. *Nature.* 1991;353:670–674.
26. Hsieh HJ, Li NQ, Frangos JA. Pulsatile and steady flow induces c-fos expression in human endothelial cells. *J Cell Physiol.* 1993;154:143–151.
27. Gentz R, Rauscher FJ III, Abate C, Curran T. Parallel association of fos and jun leucine zippers juxtaposes DNA binding domains. *Science.* 1989;243:1695–1699.
28. Matsui H, Murata Y, Hirano K, et al. Hydrogen peroxide-induced cellular injury is associated with increase in endogenous fluorescence from rat gastric mucosal epithelial cell culture: a new method for detecting oxidative cellular injury by fluorescence measurement. *J Gastroenterol.* 1998;33:318–325.
29. Dionne S, D'Agata ID, Ruemmele FM, et al. Tyrosine kinase and MAPK inhibition of TNF-alpha- and EGF-stimulated IEC-6 cell growth. *Biochem Biophys Res Commun.* 1998;242:146–150.
30. Tseng H, Peterson TE, Berk BC. Fluid shear stress stimulates mitogen-activated protein kinase in endothelial cells. *Circ Res.* 1995;77:869–878.
31. Brewster JL, de Valoir T, Dwyer ND, Winter E, Gustin MC. An osmosensing signal transduction pathway in yeast. *Science.* 1993;259:1760–1763.
32. Pai R, Ohta M, Itani RM, Sarfeh IJ, Tarnawski AS. Induction of mitogen-activated protein kinase signal transduction pathway during gastric ulcer healing in rats. *Gastroenterology.* 1998;114:706–713.
33. Suzuki H, Masaoka T, Minegishi Y, Motosugi Y, Miura S, Ishii H. Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen-activated protein kinase. *Wound Repair Regen.* 2004;12:93–99.
34. Goke M, Kanai M, Lynch-Devaney K, Podolsky DK. Rapid mitogen-activated protein kinase activation by transforming growth factor alpha in wounded rat intestinal epithelial cells. *Gastroenterology.* 1998;114:697–705.
35. Hirokawa M, Miura S, Kishikawa H, et al. Loading of mechanical pressure activates mitogen-activated protein kinase and early immediate gene in intestinal epithelial cells. *Dig Dis Sci.* 2001;46:1993–2003.
36. Fraser KA, Davison JS. Meal-induced c-fos expression in brain stem is not dependent on cholecystokinin release. *Am J Physiol.* 1993;265:R235–R239.
37. Raybould HE, Gayton RJ, Dockray GJ. Mechanisms of action of peripherally administered cholecystokinin octapeptide on brain stem neurons in the rat. *J Neurosci.* 1988;8:3018–3024.
38. Angel P, Karin M. The role of jun, fos and the AP-1 complex in cell-proliferation and transformation. *Biochim Biophys Acta.* 1991;1072:129–157.
39. Simmons JG, Hoyt EC, Westwick JK, Brenner DA, Pucilowska JB, Lund PK. Insulin-like growth factor-I and epidermal growth factor interact to regulate growth and gene expression in IEC-6 intestinal epithelial cells. *Mol Endocrinol.* 1995;9:1157–1165.
40. Lan Q, Mercurius KO, Davies PF. Stimulation of transcription factors NF kappa B and AP1 in endothelial cells subjected to shear stress. *Biochem Biophys Res Commun.* 1994;201:950–956.

# A Questionnaire-Based Survey on Screening for Gastric and Colorectal Cancer by Physicians in East Asian Countries in 2010

Yuji Naito<sup>a</sup> Kazuhiko Uchiyama<sup>a</sup> Yoshikazu Kinoshita<sup>b</sup> Shin Fukudo<sup>c</sup>  
Takashi Joh<sup>d</sup> Hidekazu Suzuki<sup>e</sup> Shin'ichi Takahashi<sup>f</sup> Fumiaki Ueno<sup>g</sup>  
Yasuhiro Fujiwara<sup>h</sup> Tetsuo Arakawa<sup>h</sup> Takayuki Matsumoto<sup>i</sup> Ki-Baik Hahm<sup>j</sup>  
Udom Kachintorn<sup>k</sup> Ari Fahrial Syam<sup>l</sup> Abdul Aziz Rani<sup>m</sup> Jose D. Sollano<sup>n</sup> Qi Zhu<sup>o</sup>

<sup>a</sup>Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, <sup>b</sup>Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Izumo, <sup>c</sup>Tohoku University School of Medicine, Sendai, <sup>d</sup>Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, <sup>e</sup>Division of Gastroenterology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, <sup>f</sup>Department of Gastroenterology, School of Medicine, Kyorin University, Kyorin, <sup>g</sup>Ofuna Chuo Hospital, Kamakura, <sup>h</sup>Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, and <sup>i</sup>Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; <sup>j</sup>Gachon University of Medicine and Science, Lee Gil Ya Cancer and Diabetes Institution, Incheon, Korea; <sup>k</sup>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok, Thailand; <sup>l</sup>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo Hospital, and <sup>m</sup>Department of Internal Medicine, Faculty of Medicine, University of Indonesia Cipto Mangunkusumo Hospital, Jakarta, Indonesia; <sup>n</sup>University of Santo Tomas, Manila, Philippines; <sup>o</sup>Rui Jing Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

## Key Words

Colorectal cancer · Gastric cancer · Screening · East Asian countries · Questionnaire-based survey

## Abstract

**Background:** The incidence of gastric cancer (GC) is high, and colorectal cancer (CRC) has significantly increased in Asian countries. **Aim:** To examine the current screening for GC and CRC within East Asia by means of a questionnaire survey. **Methods:** Representative members of the Committee of the International Gastrointestinal Consensus Symposium provided a questionnaire to physicians in six East Asian countries. **Results:** A total of 449 physicians participated in this survey. In all countries, more than 70% of physicians started GC screening between 40 and 59 years. The most popular method to screen for GC was endoscopy (92.7%),

but combination methods such as *Helicobacter pylori* (HP) antibody, barium X-ray, and tumor marker with endoscopy differed by country. For HP-positive individuals, most physicians screened every year by endoscopy, and for individuals post-HP eradication, about half of physicians (56.3%) thought there was a need to follow-up with GC screening. Among all physicians, the most common age to start CRC screening was in the 40s (39.8%) and 50s (40.9%). Based on the American Cancer Society Recommendations, a fecal occult blood test every year was the most popular method for CRC screening overall. However, among each country, this test was most popular in only Japan (76.9%) and Indonesia. In other countries, sigmoidoscopy every 5 years and total colonoscopy every 10 years were the most popular methods. **Conclusion:** There are similarities and differences in the screening of GC and CRC among East Asian countries.

Copyright © 2012 S. Karger AG, Basel

## KARGER

Fax +41 61 306 12 34  
E-Mail [karger@karger.ch](mailto:karger@karger.ch)  
[www.karger.com](http://www.karger.com)

© 2012 S. Karger AG, Basel  
0012-2823/12/0862-0094\$38.00/0

Accessible online at:  
[www.karger.com/dig](http://www.karger.com/dig)

Yuji Naito  
Molecular Gastroenterology and Hepatology  
Kyoto Prefectural University of Medicine  
465 Kajiicho Hirokoji Kawaramachi, Kamigyo-ku, Kyoto 602-8566 (Japan)  
Tel. +81 75 251 5519, E-Mail [ynaito@koto.kpu-m.ac.jp](mailto:ynaito@koto.kpu-m.ac.jp)

## Introduction

Gastric cancer (GC) is the fourth most common cancer in the world and the second leading cause of cancer-related death [1, 2]. Asian countries, including China, Japan, and Korea, show the highest incidence of GC in the world [1]. Since 1960, mass screening for GC using photofluorography has been done in Japan, and survival rates have significantly improved due to early detection of cancer [3]. Recently, other opportunistic screening methods such as endoscopy, serum pepsinogen testing, and *Helicobacter pylori* (HP) antibody testing have been used for GC screening. However, the efficacy of these methods is not clear. In addition, as new endoscopic techniques such as chromoendoscopy, narrow band imaging, confocal endoscopy, and autofluorescence have been developed, further studies on GC screening are needed.

Colorectal cancer (CRC) is one of the most common cancers worldwide, accounting for more than 1 million new cancer cases annually and approximately half a million deaths each year. The incidence of CRC in Asia is increasing [4]. Although various screening examinations, such as fecal occult blood testing, sigmoidoscopy, and colonoscopy can be used, little is known about how or when physicians recommend screening and whether patients follow different recommendations. Although Asia-Pacific consensus recommendations for CRC screening have been published [4], guidelines and recommendations for the screening and prevention of CRC in Asia have not been established. Screening and surveillance of CRC is effective for diagnosing early stages of CRC [5], but compliance rates are low in many countries worldwide [6–10].

In this survey, we intended to define the current situation concerning screening strategies for GC and CRC in East Asian countries.

## Subjects and Methods

### Subjects

Gastroenterologists, gastroenterological surgeons, and general physicians in China, Indonesia, Japan, Korea, Philippines, and Thailand were asked to fill in a questionnaire about screening for GC and CRC. All subjects work in an urban environment.

### Methods

A representative person from each country was selected from the Committee of the International Gastrointestinal Consensus Symposium, which is the international part of the Japanese Gastroenterological Association. The representative members provided a questionnaire to physicians in each country, starting at

**Table 1.** CRC screening criteria by American Cancer Society recommendation

- 1 Fecal occult blood test every year
- 2 Fecal DNA test every year
- 3 Sigmoidoscopy every 5 years
- 4 Total colonoscopy every 10 years
- 5 Barium enema every 5 years
- 6 CT colonography every 5 years

**Table 2.** Number of physicians who participated in the survey by speciality

	Gastro- enterologists	Gastro- enterological surgeons	General physicians	Total
China	26	12	0	38
Indonesia	34	0	10	44
Japan	216	11	21	248
Korea	44	0	7	51
Philippines	21	0	7	28
Thailand	18	14	8	40
Total	359	37	53	449

the beginning of July 2010 and collected responses until the end of December 2010. The questionnaire asked the following questions about GC and CRC: (1) GC: age of starting screening examinations, the most common age when screening examinations are done, and the preferred screening examination. In addition, physicians were asked about the management of HP infection in terms of the follow-up period for patient who did and did not undergo HP eradication. (2) CRC: age of starting screening examinations, the most common age when screening examinations are done, and the preferred examination for screening. The questionnaire for CRC screening criteria was based on American Cancer Society Recommendations [11] (table 1). Details of the questionnaire are shown in the Appendix.


## Results

### Characteristics of Respondents

A total of 449 physicians were enrolled in this survey. Among all countries, the number of physicians participating in this survey was largest in Japan and smallest in the Philippines (table 2).

### GC: Age of Starting Screening Examinations

Among all physicians, the most common age to start GC screening was in the 40s (54.7% of physicians; fig. 1a).



**Fig. 1.** Starting age of GC screening. **a** Among all physicians. **b** Screening by country. **c** Differences among gastroenterologists, gastroenterological surgeons, and general physicians for starting age of GC screening.

Among the countries surveyed, Korea had the largest ratio of physicians who started GC screening in the 40s (fig. 1b). In terms of physician type, 56% of gastroenterologists start GC screening in the 40s; 46 and 44% of gastroenterological surgeons start in the 40s and 50s, respectively, and 55% of general physicians start in the 40s (fig. 1c).

#### GC: Preferred Screening Examination


The most common screening method for GC was endoscopy both among all physicians (92.7%) and in each country (China, 100%; Indonesia, 100%; Japan, 89.8%; Korea, 100%; Philippines, 95.2%; Thailand, 83.3%). There were no differences among gastroenterologists, gastroenterological surgeons, and general physicians in terms of

the preference for endoscopy as the best GC screening method (92.7, 92.9, and 92.0%, respectively). However, there were several different suggestions about combination screening methods (fig. 2a). Though endoscopy was included in most combination methods, HP antibody, barium X-ray, and tumor marker surveys were also popular as part of combination screening methods for GC (fig. 2b).


#### Screening Methods for HP-Positive Patients

Data on the duration of follow-up and the methods of screening HP-positive patients were provided by 359 gastroenterologists. Results showed that 65% of gastroenterologists follow up every year (fig. 3a) and 77% of them use endoscopy (fig. 3b).








**Fig. 2.** Combination of GC screening methods used by all physicians (a) and by country (b).



**Fig. 3. a** Interval to follow-up of HP-positive patients among gastroenterologists. **b** Methods used by gastroenterologist to follow up HP-positive patients.



**Fig. 4. a** Need to follow up after HP eradication among gastroenterologists. **b** Interval of follow-up examinations for patients post-HP eradication among gastroenterologists. **c** Length of follow-up period of patients post-HP eradication among gastroenterologists.

#### Screening after HP Eradication

Among the 359 gastroenterologists who provided data on HP eradication, 202 (56.3%) thought that follow-up GC screening after HP eradication was necessary (fig. 4a). Among these 202 gastroenterologists, more than 60% perform GC screening every year (fig. 4b). The duration of follow-up varied (fig. 4c). Whole-life follow-up was the most popular response (22.9%) regarding the follow-up period; however, 42.5% answered 'unclear'.

#### CRC: Age of Starting Screening Examinations


Among all physicians, the most common ages to start CRC screening were in the 40s (39.8%) and 50s (40.9%), and more than 90% of physicians start CRC screening before 60 years (fig. 5a). Among the countries surveyed, Japan tended to start earlier compared with other countries (fig. 5b). There were no significant differences between gastroenterologists and gastroenterological surgeons in terms of starting age of screening (fig. 5c).

#### CRC: Preferred Screening Examination among Gastroenterologists

Among all gastroenterologists, fecal occult blood test every year was the most popular method (52.5%) for CRC screening (fig. 6a). However, this result was largely driven by responses of Japanese gastroenterologists, who represented the largest number of gastroenterologists (n = 216). Sigmoidoscopy every 5 years and total colonoscopy every 10 years were common responses from gastroenterologists in other countries (fig. 6b).

#### Discussion

Although a decline in the number of GC patients has been observed in Japan, China, and Korea, GC still represents a tremendous burden in each country. According to GLOBOCAN 2008, GC is the third most frequently diagnosed cancer and the second leading cause of cancer deaths in Japan, with an estimated 102,040 new cases and 50,156 cancer deaths in 2008. The overall estimated age-adjusted incidence rate in 2008 was 31.1 per 100,000 people [12]. In China, there is no systematic national vital statistics, but a retrospective sampling survey from 2004 to 2005 found that the mortality rate from GC ranked third in overall cancer mortality [13]. GC is the second most frequently diagnosed cancer in China and the third leading cause of cancer death, with an estimated 464,439 new cases and 352,315 cancer deaths in 2008. The overall estimated age-adjusted incidence rate in 2008 was 29.9



**Fig. 5.** Starting age of CRC screening. **a** Starting age of CRC screening among all physicians. **b** Starting age of CRC screening by country. **c** Differences among gastroenterologists, gastroenterological surgeons, and general physicians for starting age of CRC screening.

per 100,000 people. In Korea, GC mortality has been consistently decreasing; however, it is still a clinically important disease due to its high incidence and mortality [14]. In 2008, an estimated 28,078 new cases were diagnosed, accounting for 15.7% of new cancer cases. The incidence of disease was 43.8 per 100,000 in 2008. In Thailand, the estimated age-standardized incidence rate in 2002 of GC shows some variation with higher rates in Bangkok, which were 4.9 per 100,000 for males and 3.7 per 100,000 for females [15]. The estimated age-standardized incidence rate in 2007 of stomach cancer in the Philippines was 7.9 per 100,000 for males and 5.4 per 100,000 for fe-

males [16]. The incidence of GC in Indonesia is exceedingly rare and it has been reported to relate with the relative lack of infection with HP [17]. These statistical data include that although the number of GC patients is decreasing in Asian countries, it is still the second most common cause of death worldwide [1, 18] as well as in many Asian countries, such as China, Japan, and Korea. However, a screening program for GC has not been established in Asian countries.

According to the Asia-Pacific Working Group on GC, the optimum age for initiation of screening should be 40–45 years [19]. In particular, in high-risk regions, such as




Fig. 6. Methods for CRC screening by all physicians (a) and by country (b).

Japan and Korea, the working group recommends screening all individuals older than 40 years. In this survey, most physicians agreed about starting GC screening at 40 years.

Endoscopy was the most popular screening method for GC among physicians in this survey. In general, endoscopy is increasingly used for GC screening because of a high detection rate of superficial flat and non-ulcerative lesions that conventional barium examination cannot detect [20]. However, the sensitivity of GC detection by endoscopy compared with that of barium X-ray (photofluorography) is not clear. Although endoscopic screening is expected to be an alternative strategy to photofluorography, no studies have evaluated whether endoscopic screening reduces GC mortality. As new endoscopic tech-

niques such as chromoendoscopy, narrow band imaging, confocal endoscopy, and autofluorescence are developed, the sensitivity and detection of GC are expected to increase. Although most physicians in this survey recommend endoscopy, further study is necessary to evaluate the efficacy of endoscopy for GC screening using up-to-date screening tools.

Photofluorography has been used for GC screening in Japan since 1960 [21]. Though there is no randomized, controlled study of GC screening using photofluorography, several case-control and cohort studies dealing with photofluorography have been published [3, 22–26]. These studies indicate that GC screening with photofluorography resulted in a reduction in mortality from GC. However, data from prospective studies that define death from